Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:clinical_trial |
NCT01817112
NCT01817125 NCT01817138 NCT01817151 |
| gptkbp:dosage_form |
gptkb:Software_Solutions
|
| gptkbp:effective_date |
January 2015
|
| https://www.w3.org/2000/01/rdf-schema#label |
Natpara
|
| gptkbp:ingredients |
gptkb:parathyroid_hormone
|
| gptkbp:manufacturer |
gptkb:NPS_Pharmaceuticals
|
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:side_effect |
fatigue
headache nausea hypercalcemia |
| gptkbp:used_for |
hypoparathyroidism
|
| gptkbp:bfsParent |
gptkb:Shire_plc
|
| gptkbp:bfsLayer |
5
|